Early Cancer Detection Purple DNA Organ Rejection Monitoring Liquid Biopsy

• Product Description: Cell-Free DNA (cfDNA) Collection and Preservation System by Orsin Medical Technology

  • 1. Product Description

    ---

     

  • Orsin Medical Technology revolutionizes liquid biopsy with our next-generation cfDNA Blood Collection Tube, engineered to deliver uncompromised sample quality for precision diagnostics and research.

    Why Choose Orsin’s cfDNA Tube?

  • Ultra-Stable Preservation – Proprietary formula inhibits hemolysis and nucleases, maintaining cfDNA integrity for extended periods.

  • Clinical-Grade Reliability – Validated for NIPT, oncology, and transplant monitoring, ensuring consistency across applications.

  • Seamless Workflow Integration – Compatible with automated extraction platforms and major downstream assays (qPCR, NGS, ddPCR).

  • Innovation in Every Tube:
    Our barrier-coated interior prevents gDNA contamination, while the vacuum-sealed design ensures leak-proof safety during transit.

    Ideal for:
    ✔ Early cancer detection
    ✔ Fetal genetic screening
    ✔ Minimal residual disease (MRD) monitoring
    ✔ Pathogen DNA analysis

  • Global Compliance – Manufactured under ISO 13485 standards for guaranteed performance.

•  

• 2. Specification

  ---

   

  Parameter	Description/Options
  Tube Cap Color	Red, Lavender (Purple), Green, Gray, Blue, Yellow, Black, etc.
  Additive Type	None (Clot activator), EDTA, Heparin, Sodium Citrate, Sodium Fluoride, etc.
  Clinical Use	Serum separation, Hematology, Coagulation, Chemistry, Glucose, Blood Bank, etc.
  Nominal Volume	2ml, 3ml, 4ml, 5ml, 6ml, 7ml, 8ml, 10ml, etc.
  Draw Volume Range	±10% of nominal volume (e.g., 4.5-5.5ml for 5ml tube)
  Tube Diameter	13mm, 16mm (standard adult size)
  Tube Length	75mm, 100mm, etc.
  Material	PET plastic, Glass
  Sterilization	Gamma irradiation, EO Gas
  Expiry Period	Typically 12-36 months (from date of manufacture)
  Hemolysis Rate	≤0.1% (for most chemistry tubes)
  Clotting Time	30 mins (for serum tubes with clot activator)
  Centrifuge Speed	1300-2200g (tube material dependent)
  Safety Features	Hemogard™ closure, BD-PTS, Needle protection system
  Certifications	ISO 6710, CE Marked, FDA 510(k)

   

  Common Parameters by Tube Color (Example):

   

  Cap Color	Additive	Mixing	Inversion Count	Clinical Applications
  Red	None/Clot activator	5×	5-6	Serum chemistry, Immunology
  Lavender	K2/K3 EDTA	8-10×	8-10	Hematology (CBC, Blood Smear)
  Green	Lithium Heparin	8-10×	8-10	Plasma chemistry, STAT tests
  Gray	NaF/K Oxalate	8-10×	8-10	Glucose tolerance, Alcohol tests
  Blue	Sodium Citrate	3-4×	3-4	Coagulation tests (PT, APTT)

Clinical Performance Metrics

• 3 . Application

  ---

   

•  

• 1.Precision Oncology Solutions

• Unparalleled sensitivity for early detection

• Serial monitoring capability for dynamic conditions

• Comprehensive genomic coverage

• Streamlined workflow integration

• CLIA-certified analytical validity

• Novel biomarker discovery pipelines

• Clinical trial enrichment strategies

• Pharmacodynamic endpoint development

• Therapeutic target identification

• 2.Research and Development Applications Biomedical Innovation

• Cardiovascular event risk stratification

• Neurodegenerative disease progression tracking

• Autoimmune disorder monitoring

• Metabolic disease assessment

• 3.Chronic Disease Management

• Rapid sepsis pathogen identification

• Culture-resistant infection diagnosis

• Antimicrobial resistance profiling

• Viral load monitoring

• 4.Cutting-Edge Diagnostic Applications Next-Generation Infection Detection

• Real-time graft rejection monitoring via donor-derived DNA

• Quantitative assessment of transplant engraftment success

• Early detection of post-transplant complications

• Personalized immunosuppression adjustment

• 5.Transplant Medicine Advancements

• Safe, accurate fetal chromosomal abnormality screening

• Comprehensive genetic risk assessment from maternal circulation

• Early prediction of pregnancy-related complications

• Non-invasive fetal RhD status determination

• 6.Advanced Prenatal Care

• Early-stage tumor detection through ultra-sensitive ctDNA profiling

• Dynamic monitoring of therapeutic efficacy and emerging resistance

• Comprehensive metastatic assessment without invasive procedures

• Personalized treatment selection through longitudinal mutation tracking